Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) binding site , is showing promising outcomes in early human assessments . Ongoing research suggests that retatrutide may offer significant benefits for individuals with type , particularly regarding body mass decrease and blood sugar